NASDAQ:TCDA

Tricida - TCDA Stock Forecast, Price & News

$13.36

-0.11 (-0.82%)

(As of 08/19/2022 12:00 AM ET)

Add

Compare

Today's Range: $12.76
▼
$13.51
50-Day Range: $8.19
▼
$13.60
52-Week Range: $3.84
▼
$13.79

Volume: 317,270 shs
Average Volume: 436,475 shs
Market Capitalization: $743.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Tricida MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 2.3% Upside
$13.67 Price Target
Short Interest: Bearish
19.15% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.25
Upright™ Environmental Score
News Sentiment: -0.29
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$9.52 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.20) to ($0.94) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

1006th out of 1,116 stocks

Pharmaceutical Preparations Industry

496th out of 545 stocks

1.3

Analyst's Opinion

Consensus Rating
Tricida has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.67, Tricida has a forecasted upside of 2.3% from its current price of $13.36.
Amount of Analyst Coverage
Tricida has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
19.15% of the float of Tricida has been sold short.
Short Interest Ratio / Days to Cover
Tricida has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in Tricida has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tricida does not currently pay a dividend.
Dividend Growth
Tricida does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Tricida has received a 67.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.
Environmental Sustainability
The Environmental Impact score for Tricida is -1.25.

0.9

News and Social Media Coverage

News Sentiment
Tricida has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Tricida this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for TCDA on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Tricida to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tricida insiders have bought 179.84% more of their company's stock than they have sold. Specifically, they have bought $9,517,079.00 in company stock and sold $3,400,889.00 in company stock.
Percentage Held by Insiders
35.60% of the stock of Tricida is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.28% of the stock of Tricida is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Tricida are expected to grow in the coming year, from ($2.20) to ($0.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tricida is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tricida is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Tricida (NASDAQ:TCDA) Stock

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Tricida Trading Down 0.8 %

Shares of Tricida stock traded down $0.11 on Friday, reaching $13.36. The company had a trading volume of 317,270 shares, compared to its average volume of 436,475. The company has a debt-to-equity ratio of 584.92, a current ratio of 5.11 and a quick ratio of 5.11. The firm has a market cap of $743.74 million, a price-to-earnings ratio of -4.93 and a beta of 0.68. Tricida has a 1 year low of $3.84 and a 1 year high of $13.79. The firm's 50-day moving average price is $10.44 and its two-hundred day moving average price is $9.63.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group dropped their target price on shares of Tricida from $22.00 to $16.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th.

Insider Activity

In related news, major shareholder Venrock Healthcare Capital Par purchased 91,506 shares of the business's stock in a transaction dated Monday, June 6th. The shares were acquired at an average cost of $9.35 per share, for a total transaction of $855,581.10. Following the acquisition, the insider now owns 5,865,160 shares of the company's stock, valued at approximately $54,839,246. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Tricida news, major shareholder Brian M. Isern sold 37,339 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $13.42, for a total transaction of $501,089.38. Following the transaction, the insider now owns 732,675 shares in the company, valued at $9,832,498.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Venrock Healthcare Capital Par acquired 91,506 shares of the business's stock in a transaction on Monday, June 6th. The shares were purchased at an average price of $9.35 per share, with a total value of $855,581.10. Following the completion of the purchase, the insider now owns 5,865,160 shares in the company, valued at approximately $54,839,246. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 999,004 shares of company stock valued at $9,517,079. Corporate insiders own 35.60% of the company's stock.

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Stock News Headlines

August 17, 2022 | americanbankingnews.com

Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Brian M. Isern Sells 37,339 Shares of Stock

August 17, 2022 | americanbankingnews.com

Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Brian M. Isern Sells 214,800 Shares

August 11, 2022 | americanbankingnews.com

Tricida (NASDAQ:TCDA) Hits New 12-Month High at $12.62

August 9, 2022 | msn.com

Tricida: Q2 Earnings Insights

August 9, 2022 | benzinga.com

Tricida: Q2 Earnings Insights - Benzinga

August 9, 2022 | finance.yahoo.com

Tricida Announces Second Quarter 2022 Financial Results - Yahoo Finance

August 8, 2022 | businesswire.com

Tricida Announces Second Quarter 2022 Financial Results - Business Wire

August 7, 2022 | americanbankingnews.com

Tricida (TCDA) Scheduled to Post Earnings on Monday

August 4, 2022 | americanbankingnews.com

Tricida (NASDAQ:TCDA) Trading Up 8.1% Following Insider Buying Activity

August 4, 2022 | americanbankingnews.com

Tricida (NASDAQ:TCDA) Trading Up 8.1% on Insider Buying Activity

August 3, 2022 | americanbankingnews.com

Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Acquires $174,069.00 in Stock

August 3, 2022 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tricida, Inc. - Benzinga

August 2, 2022 | globenewswire.com

Tricida Alert: Shareholder Class Action Survives in Part Motion to Dismiss; Should Management be Held Accountable for Shareholder Losses? Contact Johnson Fistel - GlobeNewswire

August 1, 2022 | globenewswire.com

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022 - GlobeNewswire

August 1, 2022 | finance.yahoo.com

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022

July 28, 2022 | americanbankingnews.com

Tricida (NASDAQ:TCDA) Trading 3.6% Higher Following Insider Buying Activity

July 26, 2022 | seekingalpha.com

Tricida raises as 10% owner purchases shares worth of $687k - Seeking Alpha

July 26, 2022 | americanbankingnews.com

Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Venrock Healthcare Capital Par Acquires 15,000 Shares

July 26, 2022 | americanbankingnews.com

Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Venrock Healthcare Capital Par Purchases 29,199 Shares

July 21, 2022 | benzinga.com

$1.4 Million Bet On This Biotechnology Stock? 3 Stocks Insiders Are Buying - Benzinga - Benzinga

July 20, 2022 | uk.finance.yahoo.com

Tricida, Inc. (TCDA)

July 14, 2022 | streetinsider.com

Form 4 Tricida, Inc. For: Jul 12 Filed by: VHCP Co-Investment Holdings III, LLC - StreetInsider.com

July 13, 2022 | finance.yahoo.com

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer - Yahoo Finance

June 28, 2022 | seekingalpha.com

Tricida stock rises 8% as owner buys more shares (TCDA) - Seeking Alpha

June 27, 2022 | seekingalpha.com

Tricida - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Company Calendar

Last Earnings: 11/08/2021
Today: 8/19/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TCDA
CUSIP: N/A
CIK: 1595585
Web: www.tricida.com
Phone: (415) 429-7800
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.67
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +2.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-176,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -716.22%
Return on Assets: -100.79%

Debt

Debt-to-Equity Ratio: 584.92
Current Ratio: 5.11
Quick Ratio: 5.11

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.00) per share
Price / Book: -6.68

Miscellaneous

Outstanding Shares: 55,669,000
Free Float: 35,851,000
Market Cap: $743.74 million
Optionable: Not Optionable
Beta: 0.68

Key Executives

Dr. Gerrit Klaerner Ph.D. (Age 50)
Founder, Pres, CEO & Exec. Director
Comp: $992.55k

Mr. Geoffrey M. Parker (Age 57)
COO, CFO & Exec. VP
Comp: $656.28k

Mr. Robert L. McKague J.D.
Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer

Dr. Dawn Parsell Ph.D. (Age 60)
Exec. VP of Clinical Devel.
Comp: $649.17k

Ms. Annie Yoshiyama (Age 39)
VP of Fin. & Chief Accounting Officer

Jackie Cossmon
VP of Investor Relations & Communications

Mr. Edward J. Hejlek Esq. (Age 66)
J.D., Exec. VP of Intellectual Property

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCDA Stock - Frequently Asked Questions

Should I buy or sell Tricida stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCDA shares.
View TCDA analyst ratings or view top-rated stocks.
What is Tricida's stock price forecast for 2022?: 3 analysts have issued 1-year price targets for Tricida's shares. Their TCDA share price forecasts range from $7.00 to $18.00. On average, they predict the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price.
View analysts price targets for TCDA or view top-rated stocks among Wall Street analysts.
How have TCDA shares performed in 2022?: Tricida's stock was trading at $9.56 at the start of the year. Since then, TCDA stock has increased by 39.7% and is now trading at $13.36.
View the best growth stocks for 2022 here.
When is Tricida's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TCDA earnings forecast.
How were Tricida's earnings last quarter?: Tricida, Inc. (NASDAQ:TCDA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.09. During the same quarter in the prior year, the firm posted ($1.55) EPS.
What is Gerrit Klaerner's approval rating as Tricida's CEO?: 2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).
When did Tricida IPO?: (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.
What is Tricida's stock symbol?: Tricida trades on the NASDAQ under the ticker symbol "TCDA."
Who are Tricida's major shareholders?: Tricida's stock is owned by many different institutional and retail investors. Top institutional shareholders include Commodore Capital LP (3.64%), State Street Corp (0.98%), Deutsche Bank AG (0.80%), Northern Trust Corp (0.53%), Millennium Management LLC (0.40%) and Victory Capital Management Inc. (0.35%). Insiders that own company stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Kurtis R Kurimsky, Robert J Alpern, Robert Mckague, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Venrock Healthcare Capital Par and Wilhelm Stahl.
View institutional ownership trends.
How do I buy shares of Tricida?: Shares of TCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tricida's stock price today?: One share of TCDA stock can currently be purchased for approximately $13.36.
How much money does Tricida make?: Tricida (NASDAQ:TCDA) has a market capitalization of $743.74 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis.
How can I contact Tricida?: Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com.

This page (NASDAQ:TCDA) was last updated on 8/19/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Tricida - TCDA Stock Forecast, Price & News

Tricida MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability